Curanex Pharmaceuticals
CURX
11 hedge funds and large institutions have $140K invested in Curanex Pharmaceuticals in 2025 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 1 increasing their positions, 3 reducing their positions, and 5 closing their positions.
20% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 5
10% more funds holding
Funds holding: 10 → 11 (+1)
0.02% more ownership
Funds ownership: 0.05% → 0.08% (+0.02%)
32% less capital invested
Capital invested by funds: $206K → $140K (-$65.9K)
67% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DS
DRW Securities
Chicago,
Illinois
|
+$39.4K |
| 2 |
Two Sigma Investments
New York
|
+$33.6K |
| 3 |
Renaissance Technologies
New York
|
+$32.6K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$23.3K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$22.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$28.3K |
| 2 |
TSS
Two Sigma Securities
New York
|
-$23.4K |
| 3 |
Millennium Management
New York
|
-$13.8K |
| 4 |
SRL
Scientech Research LLC
Jersey City,
New Jersey
|
-$10.4K |
| 5 |
Jane Street
New York
|
-$5.66K |
CURX Hedge Fund Activity: Q4 2025 in Review
11 of the 8,270 institutional investors tracked by Wall St. Rank reported a position in Curanex Pharmaceuticals (CURX) for Q4 2025, worth a combined $140K — down 32% from $206K a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new CURX positions and 5 closed out — a net gain of 1 holder — while 1 added to existing stakes and 3 trimmed.
The largest buyer was DRW Securities, opening a new position worth an estimated $39.4K. The largest seller was UBS Group, cutting an estimated $28.3K.
- 11 institutional investors held Curanex Pharmaceuticals (CURX) as of Q4 2025, up from 10 in Q3 2025.
- Funds reported $140K of Curanex Pharmaceuticals stock for Q4 2025, down 32% quarter-over-quarter.
- 6 funds opened new Curanex Pharmaceuticals positions in Q4 2025 and 5 closed out, a net change of +1 holder.
- The largest Curanex Pharmaceuticals buyer in Q4 2025 was DRW Securities, an estimated $39.4K added.
- The largest Curanex Pharmaceuticals seller in Q4 2025 was UBS Group, an estimated $28.3K sold.
Based on aggregated 13F filings for Q4 2025.